Evidence‑Based Alternatives to Denosumab (Prolia) for Osteoporosis

First‑Line Oral and Intravenous Bisphosphonates

Oral bisphosphonates (alendronate, risedronate) are the preferred first‑line alternatives to denosumab for most patients, providing comparable fracture‑reduction, lower cost, and an established safety profile (strong evidence) [1][2].
Alendronate, risedronate, and intravenous zoledronic acid reduce hip and vertebral fractures with robust evidence [1][3].
These agents demonstrate efficacy for hip‑fracture prevention that is comparable to denosumab 1.
Intravenous zoledronic acid (once yearly) is an effective option for patients who cannot tolerate oral therapy [1][2].
Recommended treatment duration: 5 years for oral bisphosphonates and 3 years for IV zoledronic acid, followed by reassessment for a drug holiday [1][4].

Teriparatide or abaloparatide for up to 2 years provide superior vertebral and non‑vertebral fracture reduction in very high‑risk patients (strong evidence) [2][4].
Romosozumab (dual‑action agent) is an alternative for very high‑risk patients with prior fractures [2][5].
After completing anabolic therapy, patients must transition to an anti‑resorptive (bisphosphonate or denosumab) to preserve bone‑density gains [4][6].

Raloxifene or bazedoxifene reduce vertebral fractures in patients with low deep‑vein thrombosis risk (moderate evidence) [4][6].
Raloxifene also lowers breast‑cancer risk 4.
SERMs are not recommended for hip‑fracture prevention because evidence is insufficient 1.

MHT (estrogen ± progestin) may be considered only in women < 60 years or < 10 years post‑menopause who have bothersome vasomotor symptoms [4][6].
Strong recommendation against using MHT as primary osteoporosis therapy due to increased cardiovascular events, stroke, and breast‑cancer risk (high‑quality evidence) [1][3].

Oral bisphosphonates reduce vertebral fractures in men with clinically recognized osteoporosis (strong evidence) [1][3].
Evidence for other agents in men is largely extrapolated from female studies 1.

Stopping denosumab leads to rapid bone loss and a rebound increase in fracture risk (high‑quality evidence) [4][6].
An immediate transition to another anti‑resorptive (bisphosphonate, SERMs, or MHT) is required when denosumab is discontinued [4][6].
The rebound phenomenon is unique to denosumab; bisphosphonates retain residual skeletal effects for years after cessation 4.

Very high risk (severe/multiple vertebral fractures): initiate anabolic agents first [2][4].
High risk: oral bisphosphonates are preferred [1][2].
Moderate risk: oral bisphosphonates or observation with optimized calcium/vitamin D 1.
GI intolerance → IV zoledronic acid [1][2].
High breast‑cancer risk → raloxifene 4.
Age < 60 with vasomotor symptoms → consider MHT [4][6].

Generic oral bisphosphonates are the most cost‑effective option (strong evidence) [1][3].
IV zoledronic acid offers once‑yearly dosing, improving adherence 1.
Teriparatide and abaloparatide require daily injections and are expensive (moderate evidence) [4][7].

Calcitonin should be reserved for patients who cannot tolerate any other therapy; it has the weakest efficacy evidence 4.
Raloxifene is strongly discouraged as first‑line therapy because of thromboembolic risk and lack of hip‑fracture protection [1][3].
Ibandronate has less robust fracture data compared with other bisphosphonates and should be used only as an alternate therapy [2][5].

After 5 years of oral bisphosphonate therapy or 3 years of IV zoledronic acid, clinicians should reassess the need for continuation and consider a drug holiday (moderate evidence) [1][4].